Illumine Investment Management LLC Acquires New Stake in Simulations Plus, Inc. (NASDAQ:SLP)

Illumine Investment Management LLC bought a new position in Simulations Plus, Inc. (NASDAQ:SLP) in the fourth quarter, Holdings Channel.com reports. The fund bought 10,055 shares of the technology company’s stock, valued at approximately $280,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC raised its position in shares of Simulations Plus by 15.0% during the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after purchasing an additional 290,414 shares during the period. Tributary Capital Management LLC increased its stake in Simulations Plus by 21.7% in the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock valued at $11,047,000 after buying an additional 70,526 shares during the period. Royce & Associates LP lifted its position in Simulations Plus by 28.8% in the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock worth $7,602,000 after buying an additional 53,092 shares in the last quarter. Congress Asset Management Co. grew its holdings in shares of Simulations Plus by 22.5% during the 3rd quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock valued at $6,613,000 after acquiring an additional 37,914 shares in the last quarter. Finally, Stephens Inc. AR acquired a new position in shares of Simulations Plus in the fourth quarter worth $905,000. 78.08% of the stock is owned by institutional investors.

Simulations Plus Stock Performance

SLP opened at $29.21 on Friday. The firm has a market cap of $586.89 million, a P/E ratio of 73.03 and a beta of 0.83. The business has a 50 day moving average price of $31.76 and a 200 day moving average price of $31.97. Simulations Plus, Inc. has a twelve month low of $24.00 and a twelve month high of $51.22.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 19.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stephens began coverage on Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. KeyCorp lifted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.